Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication

Kyung Soo Hong; Jong Geol Jang; Jian Hur; Jong Ho Lee; Hong Nam Kim; Wonhwa Lee; June Hong Ahn

doi:10.3947/ic.2020.52.3.396

Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication

Kyung Soo Hong
, Jong Geol Jang
, Jian Hur
, Jong Ho Lee
, Hong Nam Kim
, Wonhwa Lee
, June Hong Ahn

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.

Original language	English
Pages (from-to)	396-402
Number of pages	7
Journal	Infection and Chemotherapy
Volume	52
Issue number	3
DOIs	https://doi.org/10.3947/ic.2020.52.3.396
State	Published - Sep 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Coronavirus disease 2019
Early
Eradication
Hydroxychloroquine

Access to Document

10.3947/ic.2020.52.3.396

Cite this

@article{ca22ca6f23234d29b6d63a25c855008b,

title = "Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication",

abstract = "There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95\% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.",

keywords = "Coronavirus disease 2019, Early, Eradication, Hydroxychloroquine",

author = "Hong, \{Kyung Soo\} and Jang, \{Jong Geol\} and Jian Hur and Lee, \{Jong Ho\} and Kim, \{Hong Nam\} and Wonhwa Lee and Ahn, \{June Hong\}",

note = "Publisher Copyright: {\textcopyright} 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",

year = "2020",

month = sep,

doi = "10.3947/ic.2020.52.3.396",

language = "English",

volume = "52",

pages = "396--402",

journal = "Infection and Chemotherapy",

issn = "2093-2340",

publisher = "Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, Korean Society for AIDS, Korean Society of Pediatric Infectious Diseases",

number = "3",

}

TY - JOUR

T1 - Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication

AU - Hong, Kyung Soo

AU - Jang, Jong Geol

AU - Hur, Jian

AU - Lee, Jong Ho

AU - Kim, Hong Nam

AU - Lee, Wonhwa

AU - Ahn, June Hong

N1 - Publisher Copyright: © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PY - 2020/9

Y1 - 2020/9

N2 - There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.

AB - There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.

KW - Coronavirus disease 2019

KW - Early

KW - Eradication

KW - Hydroxychloroquine

UR - https://www.scopus.com/pages/publications/85094979109

U2 - 10.3947/ic.2020.52.3.396

DO - 10.3947/ic.2020.52.3.396

M3 - Article

AN - SCOPUS:85094979109

SN - 2093-2340

VL - 52

SP - 396

EP - 402

JO - Infection and Chemotherapy

JF - Infection and Chemotherapy

IS - 3

ER -

Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this